23andMe Makes Changes to API Policy for Third-Party App Developers

Aug 24, 2018

|

NEW YORK (GenomeWeb) – Consumer genomics company 23andMe let customers know this week that it will restrict its application programming interface (API) to select third-party apps.

The firm said that in two weeks it would disable other apps' ability to access customers' 23andMe results through its API. In effect, customers that have shared their 23andMe reports with other apps through its API may no longer work.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Analysis for the Long Term

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Pricey, But Available

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Pilot Cancer Testing Program for Taiwan

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

PLOS Papers on TB Resistance, Squamous Cell Carcinoma Risk, MicroRNAs in SCC

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.

Menu

23andMe Makes Changes to API Policy for Third-Party App Developers

To read the full story....

Breaking News

Illumina Inks $750M Credit Facility With Bank of America

Castle Biosciences Q4 Revenues Down 2 Percent

CRISPR Screens Identify Host Factors Required for SARS-CoV-2 Infection

Case-Case GWAS Approach Identifies Loci That Differ in Frequency Across Psychiatric Disorders

Top Five Articles on GenomeWeb Last Week: Agilent, Hologic, Bio-Techne, and More

Bio-Rad Laboratories, Roche Enter Quality Control Partnership

The Scan

Analysis for the Long Term

Pricey, But Available

Pilot Cancer Testing Program for Taiwan

PLOS Papers on TB Resistance, Squamous Cell Carcinoma Risk, MicroRNAs in SCC

What's Popular?

Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

Spatial Omics Firms Use AGBT as Launchpad for New Tech

Fulgent Genetics Aims to Use COVID-19 Testing Gains to Grow Clinical Sequencing Business

Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Sponsorships